Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
Intestinal Research
;
: 355-378, 2020.
Article
Dans Anglais
| WPRIM
| ID: wpr-834427
ABSTRACT
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Type d'étude:
Essai clinique contrôlé
/
Guide de pratique
/
Étude observationnelle
langue:
Anglais
Texte intégral:
Intestinal Research
Année:
2020
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS